Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 2, 2013, Pages

  Monti, D ^a   Herranz, U ^b   Dal Bo, L ^c   Subissi, A ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Cross Research SA Phase I Unit   (Switzerland)

^c IPAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; CICLOPIROX; P 3051; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANDIDIASIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG PENETRATION; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; NORMAL HUMAN; ONYCHOMYCOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRICHOPHYTON RUBRUM INFECTION;

ADULT; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAILS; ONYCHOMYCOSIS; PYRIDONES; REFERENCE VALUES;

EID: 84872675795     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04529.x     Document Type: Article

References (24)

1. Roberts DT,. Onychomycosis: current treatment and future challenges. Br J Dermatol 1999; 141 (Suppl. 56): 1-4.
2. Cribier BJ, Bakshi RB,. Terbinafine in the treatment of onychomycosis: a review of its efficacy in high-risk populations and in patients with non-dermatophyte infections. Br J Dermatol 2004; 50: 414-420.
3. Baran R, Kaoukhov A,. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005; 19: 21-29.
4. Gupta AK, Ryder JE, Baran R,. The use of topical therapies to treat onychomycosis. Dermatol Clin 2003; 21: 481-489.
5. Murdan S,. Drug delivery to the nail following topical application. Int J Pharm 2002; 236: 1-26.
6. McKay DA, Schofield OM, Benton EC,. Terbinafine-induced subacute lupus erythematosus. Acta Derm Venereol (Stockh) 2004; 84: 472-474.
7. Topliss D, Gold M, Kotsirilos V, et al. Hepatic reactions with terbinafine. Aust Adverse Drug React Bull 2008; 27: 3.
8. Chen SCA, Sorrell TC,. Antifungal agents. Med J Aust 2007; 187: 404-409.
9. Monti D, Saccomani L, Chetoni P, et al. In vitro transungual permeation of ciclopirox from a hydroxypropyl chitosan-based, water soluble nail lacquer. Drug Dev Ind Pharm 2005; 31: 11-17.
10. Baran R, Tosti A, Hartmane I, et al. An innovative water soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. J Eur Acad Dermatol Venereol 2009; 23: 773-781.
11. Monti D, Saccomani L, Chetoni P, et al. Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity. Br J Dermatol 2010; 162: 311-317.
12. Mailland F, Baran R, Caserini M,. Pharmacokinetic/pharmacodynamic relationship of a new nail lacquer in the treatment of onychomycosis. Proceedings 6th EADV Spring Symposium, Bucharest 23-26 April 2009
13. Marty JP,. Amorolfine nail lacquer: a novel formulation. J Eur Acad Dermatol Venereol 1995; 4 (Suppl 1): S17-S21.
14. Guideline on the investigation of bioequivalence. CPMP/QWP/EWP/1401/98 Rev. 1, 20 January 2010.
15. Guidance for Industry, Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products FDA CDER, February 1999 OGD.
16. Susilo R, Korting HC, Greb W, et al. Nail penetration of sertaconazole with a sertaconazole-containing nail patch formulation. Am J Clin Dermatol 2006; 7: 259-262.
17. Neubert RH, Gensbügel C, Jäckel A, Wartewig S,. Different physicochemical properties of antimycotic agents are relevant for penetration into and through human nails. Pharmazie 2006; 61: 604-607.
18. Pittrof F, Gerhards J, Erni W, Klecak G,. Loceryl nail lacquer: realization of a new galenic approach to onycomycosis therapy. Clin Exp Dermatol 1992; 17 (Suppl 1): 26-28.
19. Franz TJ,. Absorption of amolorfine through human nail. Dermatology 1992; 184 (Suppl 1): 18-20.
20. Polak AM,. Preclinical data and mode of action of amorolfine. Clin Exp Dermatol 1992; 17 (Suppl.1): 8-12.
21. Kaur IP, Kakkar S,. Topical delivery of antifungal Agents Expert Opin. Drug Deliv 2010; 7: 1303-1327.
22. Bohn M, Kraemer KT,. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000; 43: S57-S69.
23. Gupta AK, Fleckman P, Baran R,. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000; 43 (4 Suppl.): S70-S80.
24. Monti D, Saccomani L, Chetoni P, et al. Validation of bovine hoof slices as model for infected human toenails: in vitro ciclopirox transungual permeation. Br J Dermatol 2011; 165: 99-105.